Corporate Vice President of Global Operations & Supply Chain, Integra Lifesciences Holdngs
Search every verified Stephen Leonard interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Stephen Leonard, Corporate Vice President of Global Operations & Supply Chain at Integra Lifesciences, has discussed the company's growth strategy and financial management. In a 2014 talk, he described how Integra combined acquisition-based growth with its core collagen technology, noting that "the combination of my background as a financier putting companies together from an acquisition perspective with the technological capabilities that Integra had was what enabled us to grow in the last 10 years." He stated that the company raised close to $800 million through various financial instruments, including banks, convertible bonds, debt, equity, and warrants, and emphasized the need for "creative financial engineering" alongside product development. Leonard also addressed product commercialization challenges. He said that Integra's artificial skin product was "extraordinary" clinically but "a disaster" commercially because the target market was initially wrong, and that the company later shifted focus to diabetic foot ulcers. He noted that when launching a dural patch product, the company changed its marketing strategy after learning that neurosurgeons valued the time savings of closing surgery 30 minutes faster over the regenerative benefits. Leonard added that Integra has few medical doctors on staff, instead partnering engineering teams with surgeons for product development.
“If you can combine a lot of the things you enjoy in your daily work and figure out how to make it a lot of fun, it makes it a lot easier to lead. At Integra, I've managed to include amazing scientific projects that change lives and generate shareholder value as a profitable company.”
“The combination of my background as a financier putting companies together from an acquisition perspective with the technological capabilities that Integra had was what enabled us to grow in the last 10 years.”
“Many companies like our own are built on the failures of others. If you add up the sunk cost inside of Integra, even when I got there, over half a billion dollars had been spent on research and development and most of those companies were bankrupt.”
“Clinically, our artificial skin product was extraordinary and could cover a patient burned over 90% of their body surface area and regenerate an entirely new dermis. Commercially, however, it was a disaster because the target market was wrong; the money is in solving diabetic foot ulcers, not burns.”
“The company has raised close to $800 million to put all these acquisitions and product development in place. We did that through every possible avenue from banks, convertible bond holders, debt holders, equity holders, and warrant holders. You have to be as creative in your financial engineering to make a company like...”
“During the first six months of this year, the capital markets in the United States shut down. No one can remember that happening before. It fundamentally changed the way all of us look at risk. We keep a lot of cash around and are always looking at financing ourselves.”
“The challenge we always had was how to grow the value of the company, which is essentially the stock price, and do it in a way which limited dilution. There's a tradeoff between borrowing, which comes with strings attached, and dilution of ownership. We manage these tradeoffs every year.”
“Competition was critical in every one of our product lines. We have unique technology but other technologies can do similar things. It's more than just having the technology; it's the ability to translate it into a product with good short-term efficacy and a good story.”
“When we launched our dural patch product, neurosurgeons didn't care about regenerating the dura; they cared that the patch allowed them to close surgery 30 minutes faster. We quickly changed our commercialization strategy to focus on that benefit, which was a hell of a selling message.”
“We have very few medical doctors in the company. Instead, we partner engineering teams with surgeon teams. The surgeons practice medicine and provide insights, while engineers develop products iteratively. This collaboration is critical to our product development.”
Stuart Essig is the CEO and President of Integra, one of the world's leading medical device companies. Before joining Integra in ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Stephen Leonard.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →